Radhi Marya, Yusuf Dalal A, AlSaffar Ghufran M, Toorani Zainab A
General Medicine, Royal College of Surgeons in Ireland (RCSI) - Medical University of Bahrain, Busaiteen, BHR.
General Surgery, Salmaniya Medical Complex, Manama, BHR.
Cureus. 2025 Mar 5;17(3):e80068. doi: 10.7759/cureus.80068. eCollection 2025 Mar.
Multiple myeloma (MM) is a quotidian malignant disorder of plasma cells. It is hallmarked by the uncontrolled growth of bone marrow plasma cells, leading to multiorgan dysfunction. Despite ongoing advancements in remedies, including chemotherapy, radiotherapy, immunomodulatory drugs, stem cell transplantations, and countless other lines of treatment, the management of MM remains a challenge. Recent studies indicate promising outcomes with chimeric antigen receptor T-cell (CAR-T) therapy, especially in patients who have previously undergone other treatments. This literature review aims to explore various facets of MM and the progress made with CAR-T therapy, emphasizing the mechanism, effectiveness, and safety profile.
多发性骨髓瘤(MM)是一种常见的浆细胞恶性疾病。其特征是骨髓浆细胞不受控制地生长,导致多器官功能障碍。尽管在治疗方面不断取得进展,包括化疗、放疗、免疫调节药物、干细胞移植以及无数其他治疗方法,但MM的治疗仍然是一项挑战。最近的研究表明,嵌合抗原受体T细胞(CAR-T)疗法取得了有前景的结果,尤其是在先前接受过其他治疗的患者中。这篇文献综述旨在探讨MM的各个方面以及CAR-T疗法取得的进展,重点关注其机制、有效性和安全性。